The latest deal supports Emergent BioSolutions' current strategy, which focuses on public health threats and revenue-generating products. The deal will also expand Emergent’s market reach and development pipeline with the addition of an adenovirus 4/7 vaccine. This vaccine was developed under contract with the US Department of Defense.
In addition, the two leading PaxVax-developed FDA-licensed vaccines, Vivotif and Vaxchora, will also provide the acquirer a huge boost as well as diversify the company’s portfolio with market-leading products, according to BioSpace.
 |
| Vivotif, a live attenuated bacterial vaccine that protects against typhoid. Made in Switzerland by Crucell. |
Founded in 2006 and based in Redwood, California, PaxVax develops and provides vaccines against infectious diseases. The company, which best known for its cholera vaccine Vaxchora and typhoid vaccine Vivotif, is a global life sciences company that working to protect life by developing specialty vaccines for civilian and military populations that address today’s health threats. Additionally, the company has also developed a proprietary oral vaccine technology based on a common virus called adenovirus, according to startup profiler Crunchbase.
Before its deal with Emergent, the company has managed to raise more than $50 million from investors, which include Ignition Partners and the Wellcome Trust. In addition to investors and funding, the company also received a grant from the US National Institutes of Health and Bill and Melinda Gates Foundation. Overall, PaxVax has raised $234.6 million in total funding.
PaxVax's investors and backers include Ignition Capital, Ignition Partners, Cerberus Capital, Blue Haven Initiative, and Pharmakon Advisors. The deal, which is subject to customary closing conditions, is expected to close this year.
Image Credit: K/Wikimedia Creative Commons
.jpg)
0 Comments